Influence of treatment on survival. (A) Overall survival of the 425 eligible patients, including the confidence interval. The 4-year survival rate was 42.0% ± 2.5%. (B) DFS of patients who received allogeneic bone marrow transplantation (BMT) was significantly better that that of patients who received at least 1 intensive consolidation course (ICC1) and those who received 2 intensive consolidation courses (ICC2).